Journals / art / 2015 / Cilt: 30 - Sayı: 1

İki farklı biyolojik ajan ile tedavi gören bir hastada nadir bir lenfoma türü

A rare kind of lymphoma in a patient on treatment with two different biological agents

Journal
art
Pages
75–78
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Treatment with systemic corticosteroids was effective.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this article, we present a rare case of cutaneous pseudolymphoma which developed after treatment with two biologics: infliximab and rituximab.
📊
Key Findings & Data:Cutaneous pseudolymphoma should be considered in the differential diagnosis of B- or T-cell lymphoma, which may present not only with local lesions, but also systemic features like fever, weight loss, night sweating, fatigue, and tiredness.
💡
Conclusion & Impact:Treatment with systemic corticosteroids was effective.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this article, we present a rare case of cutaneous pseudolymphoma which developed after treatment with two biologics: infliximab and rituximab. Cutaneous pseudolymphoma should be considered in the differential diagnosis of B- or T-cell lymphoma, which may present not only with local lesions, but also systemic features like fever, weight loss, night sweating, fatigue, and tiredness. In our case, skin biopsy with immunohistochemistry confirmed diagnosis of cutaneous pseudolymphoma. Treatment with systemic corticosteroids was effective.

Özet

Bu yazıda iki biyolojik -infliksimab and rituksimab- ile tedavinin ardından gelişen nadir bir kütanöz psödolenfoma olgusu sunuldu. Kütanöz psödolenfoma sadece lokal lezyonların değil; ateş, kilo kaybı, gece terlemesi, halsizlik ve yorgunluk gibi sistemik özelliklerin de eşlik edebildiği B veya T hücreli lenfomanın ayırıcı tanısında dikkate alınmalıdır. Bizim olgumuzda, immünohistokimya ile deri biyopsisi kütanöz psödolenfoma tanısını doğruladı. Sistemik kortikostreoidlerle tedavi etkiliydi.

🔖

Cite This Article

ASTIRKYTE, I., BUTRIMIENE, I., PETRULIONIENE, A., VENALIS, A. (2015). İki farklı biyolojik ajan ile tedavi gören bir hastada nadir bir lenfoma türü. art, Cilt: 30 - Sayı: 1, 75–78. https://ajindex.com/articles/197499

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Rijlaarsdam JU, Willemze R. Cutaneous pseudolymphomas: classification and differential diagnosis. Semin Dermatol 1994
  2. 187–96. Nihal M, Mikkola D, Horvath N, Gilliam AC, Stevens SR, Spiro TP, et al. Cutaneous lymphoid hyperplasia: a lymphoproliferative continuum with lymphomatous potential. Hum Pathol 2003
  3. 617–22. Chiang C, Romero L. Cutaneous lymphoid hyperplasia (pseudolymphoma) in a tattoo after far infrared light. Dermatol Surg 2009
  4. 1434–8. Ziemer M, Eisendle K, Müller H, Zelger B. Lymphocytic infiltration of the skin (Jessner- Kanof) but not reticular erythematous mucinosis occasionally represents clinical manifestations of Borrelia-associated pseudolymphoma. Br J Dermatol 2009
  5. 583–90. Atalar H, Sarifakioglu E, Dener C, Yanik B, Koktener A, Bayrak R. Cutaneous lymphoid hyperplasia and reactive lymphadenopathy induced by hepatitis B vaccination. Eur J Dermatol 2008
  6. 188–9. Nnebe NV, Woon C, Haines S, Dayton V, Weigel BJ. Cutaneous pseudolymphoma: an unusual presentation of a scalp mass. Pediatr Blood Cancer 2009
  7. 283–5. Ploysangam T, Breneman DL, Mutasim DF. Cutaneous pseudolymphomas. J Am Acad Dermatol 1998
  8. 877–95. McElroy MK, Kulidjian AA, Sumit R, Weidner N. Benign lymphoid hyperplasia (pseudolymphoma) of soft tissue. Hum Pathol 2011
  9. 1813–8. Guis S, Schiano de Colella JM, Bonnet N, Andrac- Meyer L, Balandraud N, Mattei JP, et al. Cutaneous pseudolymphoma associated with a TNF-alpha inhibitor treatment: etanercept. Eur J Dermatol 2008
  10. 474–6. Imafuku S, Ito K, Nakayama J. Cutaneous pseudolymphoma induced by adalimumab and reproduced by infliximab in a patient with arthropathic psoriasis. Br J Dermatol 2012
  11. 675–8. Delaporte E, Catteau B, Cardon T, Flipo RM, Lecomte- Houcke M, et al. Cutaneous pseudolymphoma during treatment of rheumatoid polyarthritis with low-dose methotrexate. Ann Dermatol Venereol 1995
  12. 521–5. Kalimo K, Räsänen L, Aho H, Mäki J, Mustikkamki UP, Rantala I. Persistent cutaneous pseudolymphoma after intradermal gold injection. J Cutan Pathol 1996
  13. 328–34. Stavrianeas NG, Katoulis AC, Bozi E, Toumbis- Ioannou E, Kanelleas AI, Makris M, et al. Cutaneous pseudolymphoma following administration of lornoxicam. Acta Derm Venereol 2007
  14. 453–5. Bagot M, Wechsler J, Perrussel M, Robbiola O, Debure C, Dubertret L. Pseudolymphoma induced by cyclosporin. Ann Dermatol Venereol 1989
  15. 894–6. Summary of product (MabThera) characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-